GlassScriptPhysician profile
Neeraj K Sachdeva
NPI 1164562005
$19,007.43
in general payments reported to CMS, 2019-2025
36 companies · $1,281 in 2025
The $1,281 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,252 · 2020: $299 · 2021: $1,052 · 2022: $4,866 · 2023: $8,597 · 2024: $1,659 · 2025: $1,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,000 · Food and Beverage: $4,462 · Education: $75.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,000.00 |
| Food and Beverage | $4,462.29 |
| Education | $75.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11,058.61 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $2,082.74 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Pfizer INC. | $808.00 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $722.20 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Intercept Pharmaceuticals, INC. | $547.15 | 2019-2025 | Ocaliva |
| Celgene Corporation | $484.21 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $320.70 | 2019-2025 | Stelara, Tremfya |
| Ferring Pharmaceuticals INC. | $309.86 | 2019-2025 | Rebyota |
| Lilly USA, LLC | $297.89 | 2023-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $280.04 | 2019-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $237.43 | 2022-2025 | Dupixent |
| Genzyme Corporation | $228.83 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $209.79 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $159.45 | 2019-2025 | |
| Qol Medical, LLC | $151.82 | 2021-2024 | Sucraid |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $139.18 | 2022-2024 | Ibsrela |
| Celltrion USA INC. | $123.70 | 2024-2025 | Zymfentra, Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.23 | 2023-2024 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $87.19 | 2021-2023 | |
| Braintree Laboratories, INC. | $81.51 | 2020-2023 | Sutab, Suflave |
| Boston Scientific Corporation | $79.87 | 2023 | |
| Janssen Pharmaceuticals, INC | $63.62 | 2019 | |
| Ucb, INC. | $57.12 | 2019 | |
| Covidien LP | $55.56 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $53.17 | 2025 | Iqirvo |
| Shionogi INC | $43.16 | 2019 | |
| Intra-Sana Laboratories | $35.87 | 2021-2022 | |
| Daiichi Sankyo INC. | $33.47 | 2021-2024 | Injectafer |
| Alnylam Pharmaceuticals INC. | $29.94 | 2024 | Givlaari |
| Ethicon US, LLC | $25.12 | 2022 | |
| Amgen INC. | $22.61 | 2023 | Amjevita, Avsola |
| Ironwood Pharmaceuticals, INC | $18.87 | 2020 | |
| Orphalan INC | $18.06 | 2024 | Cuvrior |
| Medtronic, INC. | $18.04 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $17.51 | 2024 | Utaswako Afp-L3 |
| Phathom Pharmaceuticals, INC. | $8.91 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeraj Sachdeva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.